APP and amyloidosis: Nevertheless, the patients from which the CAA brain samples were derived were also diagnosed with AD; therefore, it is not possible to rule out the contribution of parenchymal amyloid in the dysregulation of GABAergic synapse pathway, although we did not find co‐deposits of GABAergic synapse markers with parenchymal amyloid in the APP/PS1 mouse model.